Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alnylam Hopes For Strong hATTR Uptake For Vutrisiran With Longer Data

Executive Summary

The company presented 18-month data at a conference that it thinks will support strong uptake. European regulators required the 18-month data for filing; an FDA decision based on 9-month data is expected in April.

You may also be interested in...



Alnylam’s Amvuttra To Take Off From Onpattro’s Runway

The company won approval in hATTR amyloidosis polyneuropathy for the RNAi drug, which offers quarterly subcutaneous dosing versus Onpattro’s I.V. administration every three weeks.

April US FDA Approval Decisions To Cover Cardiomyopathy, CNS And China-Developed Cancer Drugs

Five novel agents have user fee goal dates in the coming month, the Pink Sheet’s US FDA Performance Tracker shows.

Alnylam Confident It Won’t Stumble On ATTR Trial Like BridgeBio

Alnylam expects success in its Phase III study in amyloid cardiomyopathy- but a competitor’s baffling failure is making analysts jittery.

Related Content

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC145752

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel